Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5660
Source ID: NCT06450652
Associated Drug: Chinese Herbal Medicine Granules
Title: CHM for T2DM & MetS
Acronym:
Status: NOT_YET_RECRUITING
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus With Metabolic Syndrome
Interventions: DRUG: Chinese Herbal Medicine granules
Outcome Measures: Primary: Fasting plasma glucose (FPG), FPG will be determined by taking a blood sample from participants who have fasted for 8-12 hours., Baseline, week 2, week 4, week 8.|Blood pressure, Blood pressure was measured thrice, after a 10 min rest, using a standard digital sphygmomanometer., Baseline, week 2, week 4, week 8. | Secondary: Framingham Stroke Risk Score (FSRS), The Framingham Stroke Risk Score (FSRS) combines stroke risk factors (sex, age, systolic blood pressure, high-density lipoprotein level, total cholesterol level, smoking, diabetes) to predict 10-year probability of stroke., Baseline, week 2, week 4, week 8.|Audit of diabetes-dependent quality of Life (ADDQoL), The ADDQOL consists of two overview items; one measures generic overall QoL and a further 19 items are concerned with the impact of diabetes on specific aspects of life. The 19 life domains are as follows: leisure activities, working life, local or long-distance journeys, holidays, physical health, family life, friendships and social life, close personal relationships, sex life, physical appearance, self-confidence, motivation to achieve things, people's reactions, feelings about the future, financial situation, living conditions, dependence on others, freedom to eat, and freedom to drink. Lower scores reflect poorer QoL. Finally, a mean weighted impact score (ADDQOL score) is calculated for the entire scale across all applicable domains., Baseline, week 4, week 8.|International Physical Activity Questionnaire Short Form (IPAQ-SF), IPAQ-SF has been recommended as a cost-effective method to assess physical activity. IPAQ-SF records the activity of four intensity levels: 1) vigorous-intensity activity such as aerobics, 2) moderate- intensity activity such as leisure cycling, 3) walking, and 4) sitting. It requires participants to recall the number of days and time spent on different intensity of activities in last 7 day., Baseline, week 2, week 4, week 8.|Anthropometric assessment, lipid panels, HbA1C, Anthropometric indices such as body height (BH), body weight (BW), waist circumference (WC) and hip circumference (HC) were measured. Body mass index \[(BMI) = BW (kg)/BH (m)2\] and waist-to-hip ratio \[(WHR) = WC (cm)/HC (cm)\] will be calculated. Lipid panels (total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein) will be assessed before and after treatment period. Hemoglobin A1c test, as known as HbA1c, measure the amount of blood glucose attached to hemoglobin, indicating the average blood glucose level for the last two to three months. For diabetic patients, an ideal HbA1c level is 48mmol/mol (6.5%) or below., Baseline, week 2, week 4, week 8.|Physiological parameters and dietary records, Wearable watch will be used to record patients' daily step count and physiological parameters. Patients' diet will be assessed by 3-day weighed dietary records (two non-consecutive weekdays and one weekend day)., Baseline, week 2, week 4, week 8.|Adverse events, All adverse events (AEs), defined as any adverse events that occur from the beginning of the participant's enrollment to the end of the trial, regardless of whether there is a causal relationship with the received treatments, that occur in the trial will be recorded., Baseline, week 2, week 4, week 8.
Sponsor/Collaborators: Sponsor: Hong Kong Baptist University
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 15
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2024-06
Completion Date: 2024-10
Results First Posted:
Last Update Posted: 2024-06-10
Locations:
URL: https://clinicaltrials.gov/show/NCT06450652